California NeuroAIDS Tissue Network

摘要 CNTN是国家神经艾滋病组织联盟（NNTC）的积极参与者，该联盟由四个 NIH资助的神经艾滋病组织库。CNTN的目标今天仍然与它成立时一样， 1998年成立，包括1）招募，临床评估，和后续行动的晚期艾滋病毒 队列，以及2）样本的采集、维护和分发给有兴趣进行 研究HIV引起的中枢和外周神经系统功能障碍的神经发病机制。 本补充要求涵盖CNTN最低限度基本操作与 在补充期间（2023年3月1日至2023年5月31日）全面运营。已请求结转资金 在这一时期，为全国过渡委员会最低限度的基本行动提供保障，许多活动大大减少 以降低成本。CNTN将继续维持约150名参与者的活体队列， 从符合《外地住房安排》专题优先事项的高度优先案件中获得尸检的目的： a）从CNS储库中根除HIV; B）HIV相关的神经认知障碍（HAND）的机制， 长期HAART的设置，和c）了解与HIV相关的合并症，包括影响 和慢性艾滋病病毒感染的风险CNTN将积累和管理活体动物（血浆、CSF、血液）库 和尸检（脑、心脏、肺、肝、肾、淋巴结、血液和CSF）标本和数据 在神经心理学、神经医学和精神病学上具有良好特征的艾滋病毒感染者。CNTN将 收集组织（例如，肠道淋巴组织、睾丸）用于新兴的中枢神经系统治疗和根除研究。独特 在国家核技术中心内，国家核技术研究中心承担了中枢神经系统HIV-1抗逆转录病毒治疗效果研究的责任 （CHARTER）样本，包括血浆、CSF、口腔拭子、皮肤活检和核酸。去识别 CHARTER数据（临床、实验室、遗传学、神经影像学和研究）已转移至NNTC 数据协调中心（DCC），现在在那里进行维护。CNTN维护CNTN和 特许标本资源。外部对去识别CNTN或CHARTER数据或标本的请求 由DCC与NNTC站点合作管理，CNTN团队配备齐全，可以及时提供 根据NNTC数据和资源分布，分析了CNTN和CHARTER标本的分布 施政纲要而最后，全国过渡委员会继续是国家核技术委员会的一个积极合作成员，具体做法是： DCC和其他NNTC站点;为更广泛的研究界提供科学和技术专业知识， NNTC指导委员会（SC）的投票成员，负责审查数据和标本的请求， 促进神经艾滋病研究;并作为NNTC神经心理学/精神病学小组委员会的领导人。 通过实现这些目标，国家电视台将继续成为国家和国际电视台。 资源服务neuroAIDS调查人员的需求。

ABSTRACT CNTN is an active participant in the National NeuroAIDS Tissue Consortium (NNTC), a partnership of four NIH-funded neuroAIDS tissue banks. The objectives of the CNTN remain the same today as it was when it was established in 1998 and encompass 1) recruitment, clinical assessment, and follow-up of a late-stage HIV cohort, and 2) collection, maintenance, and distribution of specimens to investigators interested in conducting research on the neuropathogenesis of HIV-induced central and peripheral nervous system dysfunction. This supplement is requested to cover the difference between CNTN’s minimal essential operations and operating in-full for the supplement period (03/01/2023 - 05/31/2023). Carryforward funds have been requested to cover minimal essential operations of the CNTN for this period, with many activities substantially diminished to reduce costs. CNTN will continue to maintain an in-life cohort of approximately 150 participants with the purpose of obtaining autopsies from high priority cases that are aligned with the thematic priorities of the RFA: a) HIV eradication from CNS reservoirs; b) mechanisms of HIV-associated neurocognitive disorders (HAND) in the setting of long-term HAART, and c) understanding comorbidities associated with HIV, including the effects of aging and chronic HIV-infection. CNTN will accumulate and manage a bank of in-life (plasma, CSF, blood) and autopsy (brain, heart, lung, liver, kidney, lymph node, blood, and CSF) specimens and data from persons living with HIV who are well characterized neuropsychologically, neuromedically, and psychiatrically. CNTN will collect tissues (e.g., gut lymphoid tissue, testes) for emerging CNS cure and eradication research. Unique within the NNTC, CNTN has assumed responsibility for CNS HIV-1 Antiretroviral Therapy Effects Research (CHARTER) specimens including plasma, CSF, buccal swabs, skin biopsies, and nucleic acids. De-identified CHARTER data (clinical, laboratory, genetic, neuroimaging, and research) have been transferred to the NNTC Data Coordinating Center (DCC), where they are now maintained. CNTN maintains both CNTN and CHARTER specimen resources. External requests for de-identified CNTN or CHARTER data or specimens are managed by the DCC in collaboration with NNTC sites, and the CNTN team is well equipped to provide timely distribution of both CNTN and CHARTER specimens according to NNTC data and resource distribution policies. Finally, CNTN continues to be an active collaborating member of the NNTC by: coordinating with the DCC and other NNTC sites; providing scientific and technical expertise to the wider research community as a voting member of the NNTC Steering Committee (SC), which reviews requests for data and specimens to facilitate neuroAIDS research; and as the leader of the NNTC Neuropsychology/Psychiatry subcommittee. Through the accomplishment of these objectives, the CNTN will continue to be a national and international resource serving the needs of neuroAIDS investigators.